Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Loss of apico-basal polarity often results in a malignant phenotype in epithelial tissues. Aberrant expression of polarity mediator proteins is closely associated with this process.
LRRC1
/LANO, a putative cell polarity regulator, was previously screened from our gene expression profiling in which its expression was significantly upregulated in
hepatocellular carcinoma
(
HCC
). In the present study, we provide evidences that
LRRC1
plays a potential oncogenic function in
HCC
. Consistent with the microarray data, quantitative real-time PCR results showed
LRRC1
was aberrantly upregulated in 37/56 (66.1 %, more than twofolds) of
HCC
specimens compared with adjacent non-cancerous livers. Furthermore, the cellular expression of
LRRC1
in all
HCC
cell lines examined exhibited much higher level than that in normal adult liver tissue. Functional analyses revealed that overexpression of
LRRC1
promoted, while knockdown of
LRRC1
by RNA interference inhibited the growth and colony formation of
HCC
cells. Importantly, enhanced expression of
LRRC1
conferred NIH3T3 cells the ability of cell transformation. In a xenograft tumor model, we found
LRRC1
overexpression increased the tumorigenicity of
HCC
cells. Thus, our collective findings suggest that
LRRC1
contributes to
HCC
development, and may be a potential target for therapeutic intervention in this disease.
...
PMID:Aberrant upregulation of LRRC1 contributes to human hepatocellular carcinoma. 2364 86
The molecular mechanisms underlying
hepatocellular carcinoma
(
HCC
) progression remain largely undefined. Here, we identified 176 commonly upregulated genes in
HCC
tissues based on three Gene Expression Omnibus datasets and The Cancer Genome Atlas (TCGA) cohort. We integrated survival and methylation analyses to further obtain 12 upregulated genes for validation. These genes were overexpressed in
HCC
tissues at the transcription and protein levels, and increased mRNA levels were related to higher tumor grades and cancer stages. The expression of all markers was negatively associated with overall and disease-free survival in
HCC
patients. Most of these hub genes can promote
HCC
proliferation and/or metastasis. These 12 hub genes were also overexpressed and had strong prognostic value in many other cancer types. Methylation and gene copy number analyses indicated that the upregulation of these hub genes was probably due to hypomethylation or increased gene copy numbers. Further, the methylation levels of three genes,
KPNA2
,
MCM3
, and
LRRC1
, were associated with
HCC
clinical features. Moreover, the levels of most hub genes were related to immune cell infiltration in
HCC
microenvironments. Finally, we identified three upregulated genes (
KPNA2
,
TARBP1
, and
RNASEH2A
) that could comprehensively and accurately provide diagnostic and prognostic value for
HCC
patients.
...
PMID:Identification of hub genes in hepatocellular carcinoma using integrated bioinformatic analysis. 3221 63